Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
about
The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathwaysEarly Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.The history and future of targeting cyclin-dependent kinases in cancer therapy.MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2Stimulation of hERG1 channel activity promotes a calcium-dependent degradation of cyclin E2, but not cyclin E1, in breast cancer cells.Global transcriptomic analysis of model human cell lines exposed to surface-modified gold nanoparticles: the effect of surface chemistry.Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.Analysis of factors affecting endocrine therapy resistance in breast cancer.Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.TRAIL pathway is associated with inhibition of colon cancer by protopanaxadiol.Gene expression profiling of the 8q22-24 position in human breast cancer: TSPYL5, MTDH, ATAD2 and CCNE2 genes are implicated in oncogenesis, while WISP1 and EXT1 genes may predict a risk of metastasis.Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.Emerging targeted agents in metastatic breast cancer.Endocrine resistance in breast cancer.Genetics of breast cancer bone metastasis: a sequential multistep pattern.Management of locally advanced breast cancer-perspectives and future directions.Brief Exercises Affect Gene Expression in Circulating Monocytes.Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cellsCDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis.Regulation of DNA replication-coupled histone gene expression.Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.Clinical significance and biological roles of cyclins in gastric cancerEndocrine Resistance in Breast Cancer
P2860
Q28854594-AFEEF801-758C-40AE-9318-C9D5A36BBA03Q33660573-B3509DE0-23CF-4B3F-9BAA-A97ACC085CABQ34227791-56DA56EE-8E5E-49E8-9FB6-CA606346CAC0Q34460347-11BF0152-CE57-4283-A40C-CDF342D59183Q34733320-AC3439BC-D054-41F3-A913-5BC894F05483Q35176400-A47235B8-697C-4ADF-BF30-1617DFF40C7DQ35545338-F5086D90-93C2-49C5-B5B5-F0345C857933Q35727617-D9B17349-FD02-4BF1-BFC1-20AD3DE97CC5Q36326335-C5727345-1472-4397-A10C-9B9B5185736DQ36502389-840F41EF-3954-4EDE-B3ED-F15637418A43Q36674327-441EE79E-4924-44EE-BE21-2DEFE3290E49Q36674332-0AFBA9C1-D0C7-4E55-BA50-2D5F657E1237Q37316131-27454877-F666-4A0B-B8B2-6AB2BBB0D4C8Q37407194-C69C461D-05F7-41D8-A585-F635A157F6DAQ37641588-6BF8737F-4275-4DD3-B955-83C483E5460EQ38086421-C68E72EC-F006-419D-8315-AFE2C43CB3CFQ38163573-EDD6BB51-D54A-4C17-925B-FA4D11E1D287Q38184928-E4CF8EBA-ACEA-47B5-8171-D988BEDE5258Q38350939-EC09943F-3368-4945-BCC4-7550CEB688EDQ38460232-DB9C1498-4CD7-43A0-BD13-715F2D2998BBQ38719706-08108A61-14E5-4D67-B56B-475975D2B3F4Q38949247-EE1F5B9C-E7B2-4A9E-9E4B-A4F5F250D10EQ39183079-82EEF0CC-4BA2-4B4F-A937-D5B42B2C2A7DQ41874772-CF4397C6-8AF5-41C1-BA3B-3BAAC4E48D7DQ42704187-FF8E6ED1-4D1C-47D6-A9B8-5C2F291F6F22Q44514078-5474AFFC-66F4-458D-9233-FE568BC0FB3DQ47127331-5504B00A-BCC1-4D21-92F8-A8AC6B09307CQ47321016-CBAF4C85-D760-45D9-BCF7-04861AB87F7FQ55710176-4E4C825B-AA5B-488C-A0C9-27A38920B543Q57817291-9F692B64-98D4-48A8-AE94-46BD23243799Q59072640-E54481F2-81A8-4B4D-8321-9344AFA38641
P2860
Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cyclin E2 overexpression is as ...... in human breast cancer cells.
@en
Cyclin E2 overexpression is as ...... in human breast cancer cells.
@nl
type
label
Cyclin E2 overexpression is as ...... in human breast cancer cells.
@en
Cyclin E2 overexpression is as ...... in human breast cancer cells.
@nl
prefLabel
Cyclin E2 overexpression is as ...... in human breast cancer cells.
@en
Cyclin E2 overexpression is as ...... in human breast cancer cells.
@nl
P2093
P50
P1476
Cyclin E2 overexpression is as ...... n in human breast cancer cells
@en
P2093
Andrew Stone
C Elizabeth Caldon
C Marcelo Sergio
Christine S Lee
Elizabeth A Musgrove
Jane Barraclough
Marijke N Boersma
Rob I Nicholson
Robert L Sutherland
P304
P356
10.1158/1535-7163.MCT-11-0963
P577
2012-05-07T00:00:00Z